MDS Inc. Completes Divestiture of Central Labs Operations
Central Labs provides a comprehensive range of late-stage laboratory services to global clients, including standardized assays, cardiac services, integrated data management, international laboratory study co-ordination and site support from 600 employees at six sites in
"The completion of this transaction supports the Company's strategy to focus on its MDS Nordion business," said Stephen P. DeFalco, President and Chief Executive Officer of MDS Inc. "MDS Nordion remains committed to innovation and operational excellence to further build its leadership positions in the provision of medical isotopes for molecular and diagnostic imaging, radiotherapeutics and sterilization technologies."
MDS Inc. Strategic Repositioning
There can be no assurance that MDS will complete a transaction involving MDS Pharma Services. If MDS determines that there is not an acceptable transaction, it intends to retain and invest in building the business.
About Czura Thornton
Czura Thornton is a private investment firm that has extensive experience in international business, contract research and medical laboratories. The firm is invested in the life sciences, property and transportation sectors. Further information can be found at www.czurathornton.com.
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 3,600 highly skilled people in 13 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.For further information: MEDIA: Janet Ko, (905) 267-4226, email@example.com; INVESTORS: Peter Dans, (905) 267-4230, firstname.lastname@example.org